Profile data is unavailable for this security.
About the company
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
- Revenue in USD (TTM)2.84m
- Net income in USD-24.99m
- Incorporated2018
- Employees45.00
- LocationHCW Biologics Inc2929 N Commerce Pkwy, Miramar, Fl 33025MIRAMAR 33025United StatesUSA
- Phone+1 (954) 842-2024
- Fax+1 (954) 842-2037
- Websitehttps://hcwbiologics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 41.06m | 8.00 | -- | 8.58 | -- | 38.15 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 41.34m | 73.00 | -- | 1.50 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 41.54m | 55.00 | -- | 1.39 | -- | 2.45 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Natural Alternatives International, Inc. | 127.76m | -4.11m | 42.10m | 317.00 | -- | 0.4838 | 93.56 | 0.3295 | -0.705 | -0.705 | 21.87 | 14.03 | 0.8624 | 4.23 | 12.32 | 403,041.00 | -2.77 | 4.90 | -3.11 | 5.93 | 7.90 | 15.98 | -3.22 | 3.80 | 2.59 | -2.54 | 0.0988 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 43.29m | 32.00 | -- | 2.58 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| CASI Pharmaceuticals Inc | 28.94m | -30.48m | 43.82m | 176.00 | -- | 2.83 | -- | 1.51 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Hcw Biologics Inc | 2.84m | -24.99m | 43.88m | 45.00 | -- | 3.10 | -- | 15.44 | -0.6953 | -0.6953 | 0.0791 | 0.3737 | 0.0755 | -- | 2.91 | 63,150.89 | -66.37 | -- | -78.58 | -- | 19.72 | -- | -879.53 | -- | -- | -90.86 | 0.319 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 44.08m | 8.00 | 145.83 | 20.42 | 83.28 | 7.37 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| Benson Hill Inc | 359.83m | -132.72m | 44.48m | 270.00 | -- | 0.6609 | -- | 0.1236 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Ocuphire Pharma Inc | 19.01m | -11.30m | 44.85m | 14.00 | -- | 0.9423 | -- | 2.36 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 45.18m | 75.00 | -- | 0.4994 | -- | 1.90 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Dyadic International Inc | 2.26m | -7.85m | 45.90m | 7.00 | -- | 10.15 | -- | 20.35 | -0.2724 | -0.2724 | 0.0783 | 0.1547 | 0.1769 | -- | 4.51 | 322,197.20 | -61.58 | -36.82 | -73.50 | -39.85 | 38.24 | 22.47 | -348.00 | -410.16 | -- | -- | 0.5634 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Incannex Healthcare Inc | 163.39k | -13.70m | 46.03m | -- | -- | 2.44 | -- | 281.73 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Movano Inc | 0.00 | -29.28m | 46.09m | 30.00 | -- | 7.59 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| NextCure Inc | 0.00 | -63.73m | 46.44m | 82.00 | -- | 0.4677 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Immuneering Corp | 0.00 | -54.18m | 46.56m | 65.00 | -- | 0.5914 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Data as of May 16 2024. Currency figures normalised to HCW Biologics Inc's reporting currency: US Dollar USD
2.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HighTower Advisors LLCas of 31 Mar 2024 | 179.81k | 0.50% |
| Avantax Planning Partners, Inc.as of 31 Mar 2024 | 179.78k | 0.50% |
| Geode Capital Management LLCas of 31 Dec 2023 | 134.44k | 0.37% |
| Cresset Asset Management LLCas of 31 Dec 2023 | 131.99k | 0.37% |
| Pullen Investment Management LLCas of 31 Mar 2024 | 85.12k | 0.24% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 84.70k | 0.24% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 42.65k | 0.12% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 37.65k | 0.11% |
| AE Wealth Management LLCas of 31 Dec 2023 | 30.00k | 0.08% |
| Two Sigma Investments LPas of 31 Dec 2023 | 22.64k | 0.06% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
